Bridging of chronic oral anticoagulation with enoxaparin in patients with atrial fibrillation: Results from the prospective brave registry

Cardiovascular Therapeutics

Volumn 27, Issue 4, 2009, Pages 230-238

  Hammerstingl, C ^a   Schmitz, A ^a   Fimmers, R ^b   Omran, H ^a  

^a ST MARIEN HOSPITAL   (Germany)

^b Institut fur Medizinische Biometrie   (Germany)

Author keywords

Anticoagulation; Atrial fibrillation; Low molecular weight heparin; Perioperative management; Stratification

Indexed keywords

ANTICOAGULANT AGENT; ANTIVITAMIN K; ENOXAPARIN; LOW MOLECULAR WEIGHT HEPARIN; PHENPROCOUMON; WARFARIN;

ADULT; AGED; AMBULATORY CARE; ANTICOAGULATION; ARTICLE; BLEEDING; CONTROLLED STUDY; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HEART ATRIUM FIBRILLATION; HOSPITAL PATIENT; HUMAN; INJECTION SITE BLEEDING; KIDNEY DISEASE; KIDNEY FAILURE; KIDNEY FUNCTION; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; OUTPATIENT CARE; POSTOPERATIVE HEMORRHAGE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK ASSESSMENT; THROMBOCYTOPENIA; THROMBOEMBOLISM;

ADMINISTRATION, ORAL; AGED; ANTICOAGULANTS; ATRIAL FIBRILLATION; ENOXAPARIN; FEMALE; HEMORRHAGE; HUMANS; MALE; MIDDLE AGED; PERIOPERATIVE CARE; PROSPECTIVE STUDIES; REGISTRIES; RENAL INSUFFICIENCY; RISK FACTORS;

EID: 70449489644     PISSN: 17555914     EISSN: 17555922     Source Type: Journal    
DOI: 10.1111/j.1755-5922.2009.00099.x     Document Type: Article

References (39)

1. Heeringa J, Van Der Kuip DA, Hofman A, et al. Prevalence, incidence and lifetime risk of atrial fibrillation: The Rotterdam study. Eur Heart J 2006 27 : 949 953.
2. Halperin JL, Hart RG. Atrial fibrillation and stroke: New ideas, persisting dilemmas. Stroke 1988 19 : 937 941.
3. Furberg CD, Psaty BM, Manolio TA, Gardin JM, Smith VE, Rautaharju PM. Prevalence of atrial fibrillation in elderly subjects (the Cardiovascular Health Study). Am J Cardiol 1994 74 : 236 241.
4. Prystowsky EN, Benson DW Jr., Fuster V, et al. Management of patients with atrial fibrillation. A Statement for Healthcare Professionals. From the Subcommittee on Electrocardiography and Electrophysiology, American Heart Association. Circulation 1996 93 : 1262 1277.
5. Miyasaka Y, Barnes ME, Gersh BJ, et al. Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and implications on the projections for future prevalence. Circulation 2006 114 : 119 125.
6. Vidaillet H, Granada JF, Chyou PH, et al. A population-based study of mortality among patients with atrial fibrillation or flutter. Am J Med 2002 113 : 365 370.
7. Wang TJ, Larson MG, Levy D, et al. Temporal relations of atrial fibrillation and congestive heart failure and their joint influence on mortality: The Framingham Heart Study. Circulation 2003 107 : 2920 2925.
8. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: The Framingham Study. Stroke 1991 22 : 983 988.
9. The Stroke Prevention in Atrial Fibrillation Investigators. Predictors of thromboembolism in atrial fibrillation: I. Clinical features of patients at risk. Ann Intern Med 1992 116 : 1 5.
10. Petersen P, Boysen G, Godtfredsen J, Andersen ED, Andersen B. Placebo-controlled, randomised trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation. The Copenhagen AFASAK study. Lancet 1989 1 : 175 179.
11. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials. Arch Intern Med 1994 154 : 1449 1457.
12. Singer DE, Albers GW, Dalen JE, Go AS, Halperin JL, Manning WJ. Antithrombotic therapy in atrial fibrillation: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004 126 : 429S 456S.
13. Fuster V, Ryden LE, Cannom DS, et al. ACC/AHA/ESC 2006 Guidelines for the Management of Patients with Atrial Fibrillation. A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation). J Am Coll Cardiol 2006 48 : e149 246.
14. Douketis JD, Berger PB, Dunn AS, Jaffer AK, Spyropoulos AC, Becker RC, Ansell J. The Perioperative management of antithrombotic therapy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008 133 : 299S 339.
15. Rowan SB, Bailey DN, Bublitz CE, Anderson RJ. Trends in anticoagulation for atrial fibrillation in the U.S.: An analysis of the national ambulatory medical care survey database. J Am Coll Cardiol 2007 49 : 1561 1565.
16. Levine MN, Raskob G, Landefeld S, Kearon C. Hemorrhagic complications of anticoagulant treatment. Chest 2001 119 : 108S 1021S.
17. Ryan TP, Sloand JA, Winters PC, Corsetti JP, Fisher SG. Chronic kidney disease prevalence and rate of diagnosis. Am J Med 2007 120 : 981 986.
18. McClellan WM, Langston RD, Presley R. Medicare patients with cardiovascular disease have a high prevalence of chronic kidney disease and a high rate of progression to end-stage renal disease. J Am Soc Nephrol 2004 15 : 1912 1919.
19. Spinler SA, Inverso SM, Cohen M, Goodman SG, Stringer KA, Antman EM. Safety and efficacy of unfractionated heparin versus enoxaparin in patients who are obese and patients with severe renal impairment: Analysis from the ESSENCE and TIMI 11B studies. Am Heart J 2003 146 : 33 41.
20. Collet JP, Montalescot G, Choussat R, Lison L, Ankri A. Enoxaparin in unstable angina patients with renal failure. Int J Cardiol 2001 80 : 81 82.
21. Omran H, Hammerstingl C, Paar WD. Perioperative bridging with enoxaparin. Results of the prospective BRAVE registry with 779 patients. Med Klin (Munich) 2007 102 : 809 815.
22. Hammerstingl C, Tripp C, Schmidt H, von der Recke G, Omran H. Periprocedural bridging therapy with low-molecular-weight heparin in chronically anticoagulated patients with prosthetic mechanical heart valves: Experience in 116 patients from the prospective BRAVE registry. J Heart Valve Dis 2007 16 : 285 292.
23. Federal Institute for Medicinal Products and Medical Devices. German drug law (Arzneimittelgesetz - AMG) of the Federal Republic of Germany. http://www.bfarm.de/cln-030/nn-891668/SharedDocs/Publikationen/EN/BfArM/service/ AMG-en,templateId=raw,property=publicationFile.pdf/AMG-en.pdf. Accessed on 9. February 2009.
24. Gage BF, Waterman AD, Shannon W, Boechler M, Rich MW, Radford MJ. Validation of clinical classification schemes for predicting stroke: Results from the National Registry of Atrial Fibrillation. JAMA 2001 285 : 2864.
25. Dunn AS, Turpie AG. Perioperative management of patients receiving oral anticoagulants: A systematic review. Arch Intern Med 2003 163 : 901 908.
26. Ickx BE, Steib A. Perioperative management of patients receiving vitamin K antagonists. Can J Anaesth 2006 53 : S113 122.
27. Omran H, Hammerstingl C, Schmidt H, von der Recke G, Paar WD, Luderitz B. A prospective and randomized comparison of the safety and effects of therapeutic levels of enoxaparin versus unfractionated heparin in chronically anticoagulated patients undergoing elective cardiac catheterization. Thromb Haemost 2003 90 : 267 271.
28. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976 16 : 31 41.
29. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. The GUSTO investigators. N Engl J Med 1993 329 : 673 682.
30. Chesebro JH, Knatterud G, Roberts R, et al. Thrombolysis in Myocardial Infarction (TIMI) Trial, Phase I: A comparison between intravenous tissue plasminogen activator and intravenous streptokinase. Clinical findings through hospital discharge. Circulation 1987 76 : 142 154.
31. Garcia DA, Regan S, Henault LE, Upadhyay A, Baker J, Othman M, Hylek EM. Risk of thromboembolism with short-term interruption of warfarin therapy. Arch Intern Med 2008 168 : 63 69.
32. Fried LF, Shlipak MG, Crump C, et al. Renal insufficiency as a predictor of cardiovascular outcomes and mortality in elderly individuals. J Am Coll Cardiol 2003 41 : 1364 1372.
33. Lim W, Dentali F, Eikelboom JW, Crowther MA. Meta-analysis: Low-molecular-weight heparin and bleeding in patients with severe renal insufficiency. Ann Intern Med 2006 144 : 673 684.
34. Ferreira I, Dos L, Tornos P, Nicolau I, Permanyer-Miralda G, Soler-Soler J. Experience with enoxaparin in patients with mechanical heart valves who must withhold acenocumarol. Heart 2003 89 : 527 530.
35. Hammerstingl C, Omran H, Tripp C, Poetsch B. How useful is determination of antifactor Xa activity to guide bridging therapy with enoxaparin? A pilot study. Thromb Haemost 2009 101 : 325 332.
36. Rivas-Gandara N, Ferreira-Gonzalez I, Tornos P, et al. Enoxaparin as bridging anticoagulant treatment in cardiac surgery. Heart 2008 94 : 205 210.
37. Berkowitz SD, Stinnett S, Cohen M, Fromell GJ, Bigonzi F. Prospective comparison of hemorrhagic complications after treatment with enoxaparin versus unfractionated heparin for unstable angina pectoris or non-ST-segment elevation acute myocardial infarction. Am J Cardiol 2001 88 : 1230 1234.
38. Green B, Greenwood M, Saltissi D, Westhuyzen J, Kluver L, Rowell J, Atherton J. Dosing strategy for enoxaparin in patients with renal impairment presenting with acute coronary syndromes. Br J Clin Pharmacol 2005 59 : 281 290.
39. Bick RL, Fareed J. Low molecular weight heparins: Differences and similarities in approved preparations in the United States. Clin Appl Thromb Hemost 1999 5 (Suppl 1 S63 66.